What does this research mean for the field?

Implementation of high-sensitivity cardiac troponin assays and Universal Definition recommendations does not change the rate of myocardial infarction or cardiovascular death, despite increasing the recognition of myocardial injury. Novelty: ClaimNovelty.NOVEL_FINDING. Consensus alignment: ConsensusAlignment.NEUTRAL.

What question did this study set out to answer?

To evaluate the clinical impact of implementing a high-sensitivity cardiac troponin assay and the Universal Definition of Myocardial Infarction on diagnostic reclassification, treatments, and clinical outcomes.

July 8, 2026CirculationOpen Access

High-Sensitivity Cardiac Troponin and the Universal Definition of Myocardial Infarction

Q: What is the clinical evidence from this study?

Study design: RCT. Population: Suspected acute coronary syndrome (n=48282). Intervention: Implementation of high-sensitivity cardiac troponin I assay and Universal Definition of Myocardial Infarction recommendations vs. Contemporary troponin assay and existing diagnostic threshold. Primary outcome: Myocardial infarction (type 1 or type 4b) or cardiovascular death at 1 year (HR 1.00, 95% CI 0.82-1.21).

View Full Paper

Ask AI

Bookmark

Key result

High-sensitivity cardiac troponin fails to reduce 1-year MI or cardiovascular death in type 1 MI.

HR 1.00
95% CI 0.82-1.21
n=48,282

Why the study?

The clinical implications of implementing high-sensitivity cardiac troponin testing and the Universal Definition of Myocardial Infarction recommendations were not well understood.

Does the implementation of a high-sensitivity cardiac troponin I assay and the Universal Definition of Myocardial Infarction improve the composite outcome of myocardial infarction or cardiovascular death in patients with suspected acute coronary syndrome?

Population

48 282 consecutive patients with suspected acute coronary syndrome

Comparison

Implementation of high-sensitivity cardiac troponin and Universal Definition recommendations vs pre-implementation care

Design

Stepped-wedge cluster randomized controlled trial prespecified secondary analysis

Follow-up

1 year

Authors

ACAndrew R. ChapmanInterventional Cardiology PAPhilip D AdamsonInterventional Cardiology ASAnoop ShahInterventional Cardiology

Discussion

Member takes

Implication

No outcome benefit despite increased MI detection; challenges detection-alone expectations and leaves open targeted therapies for type 2 injury.

Key Points

To evaluate the clinical impact of implementing a high-sensitivity cardiac troponin assay and the Universal Definition of Myocardial Infarction on diagnostic reclassification, treatments, and clinical outcomes.
Stepped-wedge cluster randomized controlled trial across 10 sites enrolling 48 282 consecutive patients (mean age 61±17 years, 47% women) with suspected acute coronary syndrome (NCT01852123).
Patients were evaluated using high-sensitivity cardiac troponin I and classified according to the Universal Definition of Myocardial Infarction during validation (n=18 978) and implementation (n=29 304) phases.
The primary outcome was subsequent type 1 or 4b myocardial infarction or cardiovascular death at 1 year, alongside secondary outcomes including noncardiovascular and all-cause death.
Implementation increased diagnoses of type 1 myocardial infarction by 11% (510/4471), type 2 myocardial infarction by 22% (205/916), acute myocardial injury by 36% (443/1233), and chronic myocardial injury by 43% (389/898).
Compared with no myocardial injury, 1-year primary outcome risk was elevated across all categories, highest in type 1 myocardial infarction (cause-specific HR 5.64 [95% CI, 5.12–6.22]), whereas noncardiovascular death was highest in acute myocardial injury (cause-specific HR 2.65 [95% CI, 2.33–3.01]).
Despite increased antiplatelet or anticoagulant therapy (43% vs 61%) and revascularization (35% vs 44%) in type 1 myocardial infarction, the primary outcome remained unchanged (cause-specific HR 1.00 [95% CI, 0.82–1.21]), with no changes in treatment or outcomes observed for type 2 infarction or myocardial injury.

Study Design

Type

RCT (n=48,282)

Blinding

Open-label

Randomization

stepped-wedge cluster randomized

Multicenter

Yes

Structured PICO

Population

48,282 consecutive patients (mean age 61, 47% female) with suspected acute coronary syndrome across 10 hospitals in Scotland, followed for 1 year.

Intervention

Implementation of a high-sensitivity cardiac troponin I (hs-cTnI) assay (ARCHITECT STAT high-sensitive troponin I assay) with sex-specific 99th centile thresholds (34 ng/L in men, 16 ng/L in women) and the recommendations of the Universal Definition of Myocardial Infarction to guide clinical decisions.

Comparator

Standard care using a contemporary troponin I assay and existing diagnostic thresholds (validation phase of at least 6 months).

Outcome

Composite of myocardial infarction (type 1 or type 4b) or cardiovascular death at 1 year, adjudicated by a blinded panel.composite

Main Result

Hazard Ratio: 1 (95% CI 0.82–1.21)

Implementing high-sensitivity cardiac troponin testing increases the detection of myocardial injury and type 2 MI but does not improve 1-year clinical outcomes, highlighting a gap in evidence-based treatments for these newly identified high-risk patients.

Limitations

Moderate agreement for the classification of type 2 myocardial infarction or myocardial injury
Risk of diagnostic misclassification
Serial cardiac troponin measurements were only undertaken in 77% of patients
Missing admission or discharge letters prevented definitive diagnosis adjudication in 12% of patients
Restricted to patients with suspected acute coronary syndrome, limiting generalizability to all patients with troponin measured
Only moderate agreement between adjudicators for the classification of type 2 myocardial infarction or myocardial injury

Cite This Study

Chapman et al. (2019) conducted an RCT in Suspected acute coronary syndrome (n=48,282). Implementation of high-sensitivity cardiac troponin I assay and Universal Definition of Myocardial Infarction recommendations vs. Contemporary troponin assay and existing diagnostic threshold was evaluated on Myocardial infarction (type 1 or type 4b) or cardiovascular death at 1 year (HR 1.00, 95% CI 0.82-1.21). Implementation of high-sensitivity cardiac troponin assays did not reduce the primary outcome of myocardial infarction or cardiovascular death at 1 year in patients with type 1 myocardial infarction (HR 1.00).

synapsesocial.com/papers/6a4e6a6cfc68164f0b3a4fc7 https://doi.org/10.1161/circulationaha.119.042960

View Full Paper

Ask AI

Bookmark

Implication

No outcome benefit despite increased MI detection; challenges detection-alone expectations and leaves open targeted therapies for type 2 injury.

High-Sensitivity Cardiac Troponin and the Universal Definition of Myocardial Infarction

Discussion

Member takes

Implication

Key Points

Study Design

Structured PICO

Main Result

Limitations

Cite This Study

High-Sensitivity Cardiac Troponin and the Universal Definition of Myocardial Infarction

Discussion

Member takes

Implication

Key Points

Study Design

Structured PICO

Main Result

Limitations

Cite This Study

Also Consider

Also Consider